潜伏結核感染の検出の世界市場

潜伏結核感染の検出の世界市場は2030年までに22億米ドルに到達

2024年に18億米ドルと推定される潜伏結核感染の検出の世界市場は、2024年から2030年にかけてCAGR 3.6%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるQFTプラスブランドは、CAGR 3.0%を記録し、分析期間終了時には14億米ドルに達すると予想されます。その他のブランド・セグメントの成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は4億8,760万米ドルと推定、中国はCAGR6.6％で成長予測

米国の潜伏結核感染の検出市場は、2024年に4億8,760万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億4,110万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5%と2.8%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の潜伏結核感染の検出市場- 主要動向と促進要因まとめ

潜在性結核感染症（LTBI）とは何か、なぜ早期発見が重要なのか？

潜在性結核感染症（LTBI）とは、結核菌に感染しているにもかかわらず、活動的な症状や疾患の徴候を示さない場合に発症します。LTBIの人は感染力はありませんが、特に免疫力が低下すると活動性結核を発症するリスクがあります。重篤な健康合併症を引き起こし、他の人に感染する可能性のある活動性結核への進行を防ぐには、LTBIの早期発見と治療が極めて重要です。LTBIの診断には通常、皮膚検査や血液検査が行われ、体内の結核菌の存在を検出します。

世界の結核の罹患率の増加、特にヘルスケアのインフラが限られている新興諸国における結核の罹患率の増加が、先進的なLTBI検出法の需要に拍車をかけています。従来の皮膚検査が標準的であったが、インターフェロン-γ放出測定法（IGRA）のような新しい血液ベースの検査が、その精度の高さと迅速な結果提供能力により人気を集めています。LTBIを正確に検出することは、結核の蔓延を抑制し、活動性結核の発症を予防するための治療を適時に開始するために不可欠です。

診断技術の進歩はLTBI検出市場にどのような影響を与えているか？

診断技術の進歩により、LTBI検出の精度、スピード、アクセシビリティが大幅に向上しています。PCRベースの検査などの分子診断法は、結核菌を早期に検出するために使用されるようになってきており、従来の方法と比較してより迅速な結果と高い感度を提供しています。さらに、携帯型やポイントオブケア型の診断ツールの開発により、特に検査室のインフラが不足している遠隔地や資源の限られた環境でのLTBI検査へのアクセスが改善されつつあります。これらの技術革新は、ヘルスケア従事者、HIV感染者、活動性結核患者と密接に接触している人々など、結核のリスクが高い集団におけるLTBIの同定に極めて重要です。

QuantiFERON-TBゴールドテストのような新しい血液検査も、BCGワクチン接種歴などの要因に影響される可能性のあるツベルクリン皮膚テスト（TST）と比較して、LTBIを診断するためのより信頼性の高い方法を提供することで、検出を改善しています。さらに、デジタルヘルスツールと遠隔医療を診断プロセスに統合することで、LTBI検査の範囲と効率が拡大しています。これらの進歩により、活動性結核に進行するリスクのある個人の特定が容易になり、最終的には結核の世界的負担の軽減に寄与しています。

LTBI検出市場の成長促進要因は何か？

LTBI検出市場の成長の主な促進要因は、結核の世界的有病率の増加と、より正確で効率的な検出方法の必要性です。結核は、特に低・中所得国において、依然として公衆衛生上の大きな懸念事項であるため、LTBIを早期に特定するための信頼性が高く費用対効果の高い診断ツールに対する需要が高まっています。特に結核有病率の高い地域からの世界の移民の増加も、LTBIのスクリーニングと検出に対する需要の増加に寄与しています。

さらに、各国政府や保健機関が潜在感染を標的とした結核撲滅への取り組みを強化する中、早期診断と治療がより重視されています。血液検査や分子診断などの診断技術の進歩により、LTBI検出のスピードと精度が向上し、高リスク集団にとってより利用しやすく手頃な価格となっています。結核撲滅を目的とした世界の保健活動の拡大や資金援助は、LTBI検出が世界の結核対策プログラムの不可欠な一部であることを確実にし、市場の成長をさらに後押ししています。

LTBI検出市場の主な成長促進要因は何か？

LTBI検出市場の成長は、世界の結核罹患率の増加、より迅速で正確な診断方法に対する需要の高まり、結核の蔓延を防ぐためにLTBIを検出して治療することの重要性に対する意識の高まりなど、いくつかの要因によってもたらされます。結核撲滅を目的とした世界の保健プログラムの拡大と診断技術の進歩により、早期発見法へのアクセスが拡大しています。さらに、国境を越えた人々の移動が増加し、予防ヘルスケアが重視されるようになったことも、世界のLTBI検査の需要を後押ししています。各国が結核対策を優先し続ける中、効果的なLTBIの検出とスクリーニングの需要は今後も伸び続け、結核との闘いが世界保健活動の最前線であり続けることが確実となるであろう。

セグメント

ブランド（QFT-Plusブランド、その他ブランド）、検査タイプ（ツベルクリン皮膚テストタイプ、インターフェロンγ放出アッセイテストタイプ）、最終用途（診断ラボ最終用途、病院／診療所最終用途、学術・研究機関最終用途）、用途（肺結核家庭内接触者用途、PLHIV用途、その他用途）

調査対象企業の例

• Abbott Laboratories
• ARKRAY, Inc.
• Becton, Dickinson and Company（BD）
• Beijing Wantai Biological Pharmacy
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Cepheid
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• Lionex GmbH
• Luminex Corporation
• Oxford Immunotec Global PLC
• Par Pharmaceutical, Inc.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Sanofi S.A.
• SD Biosensor, Inc.
• Serum Institute of India Pvt. Ltd.
• Thermo Fisher Scientific Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Latent Tuberculosis Infection Detection Market to Reach US$2.2 Billion by 2030

The global market for Latent Tuberculosis Infection Detection estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. QFT-Plus Brand, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Other Brands segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$487.6 Million While China is Forecast to Grow at 6.6% CAGR

The Latent Tuberculosis Infection Detection market in the U.S. is estimated at US$487.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$441.1 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Latent Tuberculosis Infection Detection Market - Key Trends & Drivers Summarized

What Is Latent Tuberculosis Infection (LTBI) and Why Is Early Detection Critical?

Latent Tuberculosis Infection (LTBI) occurs when a person is infected with the tuberculosis (TB) bacteria but does not exhibit active symptoms or show signs of disease. People with LTBI are not contagious, but they are at risk of developing active TB, especially if their immune system becomes weakened. Early detection and treatment of LTBI are crucial to prevent the progression to active TB, which can cause serious health complications and be transmitted to others. The diagnostic process for LTBI typically involves skin tests or blood tests that detect the presence of the TB bacteria in the body.

The increasing incidence of TB globally, particularly in developing countries with limited healthcare infrastructure, has spurred the demand for advanced LTBI detection methods. While traditional skin tests have been the standard, newer blood-based tests, such as the interferon-gamma release assays (IGRAs), are gaining popularity due to their greater accuracy and ability to provide quicker results. Accurate detection of LTBI is essential for controlling the spread of TB and for initiating timely treatment to prevent the development of active TB.

How Are Advancements in Diagnostic Technologies Impacting the LTBI Detection Market?

Advancements in diagnostic technologies have significantly improved the accuracy, speed, and accessibility of LTBI detection. Molecular diagnostics, such as PCR-based tests, are increasingly being used to detect TB bacteria at an early stage, providing faster results and greater sensitivity compared to traditional methods. Additionally, the development of portable and point-of-care diagnostic tools is improving access to LTBI testing, particularly in remote or resource-limited settings where laboratory infrastructure may be lacking. These innovations are crucial for identifying LTBI in populations that are at high risk for TB, such as healthcare workers, individuals living with HIV, and those in close contact with active TB patients.

Newer blood tests, such as the QuantiFERON-TB Gold test, are also improving detection by offering a more reliable method for diagnosing LTBI compared to the tuberculin skin test (TST), which can be influenced by factors such as prior BCG vaccination. Furthermore, the integration of digital health tools and telemedicine into the diagnostic process is expanding the reach and efficiency of LTBI testing. These advancements are making it easier to identify individuals who are at risk for progressing to active TB, ultimately helping reduce the global burden of TB.

What Are the Primary Drivers of the LTBI Detection Market's Growth?

The primary drivers behind the growth of the LTBI detection market are the increasing global prevalence of tuberculosis and the need for more accurate, efficient detection methods. As TB remains a major public health concern, particularly in low-income and middle-income countries, there is growing demand for reliable and cost-effective diagnostic tools to identify LTBI early. The rise in global migration, particularly from regions with high TB prevalence, is also contributing to the increased demand for LTBI screening and detection.

Furthermore, as governments and health organizations intensify efforts to eliminate TB by targeting latent infections, there is greater emphasis on early diagnosis and treatment. Advancements in diagnostic technology, such as blood-based tests and molecular diagnostics, are improving the speed and accuracy of LTBI detection, making them more accessible and affordable for high-risk populations. The expansion of global health initiatives and funding aimed at TB eradication is further propelling market growth, ensuring that LTBI detection is an integral part of global TB control programs.

What Are the Key Growth Drivers for the LTBI Detection Market?

The growth in the LTBI detection market is driven by several factors, including the increasing incidence of tuberculosis globally, the rising demand for faster and more accurate diagnostic methods, and growing awareness about the importance of detecting and treating LTBI to prevent the spread of TB. The expansion of global health programs aimed at TB eradication, along with advancements in diagnostic technologies, is providing greater access to early detection methods. Additionally, the increasing movement of people across borders and the greater emphasis on preventive healthcare are also driving the demand for LTBI testing worldwide. As countries continue to prioritize TB control, the demand for effective LTBI detection and screening will continue to grow, ensuring that the fight against tuberculosis remains at the forefront of global health efforts.

SCOPE OF STUDY:

The report analyzes the Latent Tuberculosis Infection Detection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Brand (QFT-Plus Brand, Other Brands); Test Type (Tuberculin Skin Test Type, Interferon Gamma Released Assay Test Type); End-Use (Diagnostic Laboratories End-Use, Hospitals / clinics End-Use, Academic & Research Institutions End-Use); Application (Household Contacts with Pulmonary TB Application, PLHIV Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories
• ARKRAY, Inc.
• Becton, Dickinson and Company (BD)
• Beijing Wantai Biological Pharmacy
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Cepheid
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• Lionex GmbH
• Luminex Corporation
• Oxford Immunotec Global PLC
• Par Pharmaceutical, Inc.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Sanofi S.A.
• SD Biosensor, Inc.
• Serum Institute of India Pvt. Ltd.
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Latent Tuberculosis Infection Detection - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global TB Elimination Initiatives Throw the Spotlight on Early Latent TB Detection Technologies
  • High Prevalence of Latent TB in High-Burden Regions Expands Addressable Market Opportunity
  • Integration of Latent TB Screening in Routine Health Programs Spurs Adoption Across Primary Healthcare Settings
  • Development of Novel Biomarker-Based Diagnostic Tools Propels Market Growth Through Higher Accuracy and Specificity
  • Adoption of Interferon Gamma Release Assays (IGRAs) Strengthens Business Case for Blood-Based Latent TB Testing
  • Scaling National Screening Programs in Developing Countries Generates Demand for Affordable and Rapid Diagnostic Kits
  • Mandatory Pre-Employment and Immigration Screening Protocols Drive Growth in Occupational and Travel Health Markets
  • Increasing Research Investments in Latent TB Immunology Accelerates Diagnostic Innovation and Pipeline Expansion
  • Emergence of AI and Data Analytics in TB Risk Stratification Enhances Precision Screening and Drives Adoption
  • Heightened Focus on Preventing TB Reactivation in Immunocompromised Populations Propels Screening Demand
  • WHO Guidelines Endorsing Systematic Testing in High-Risk Groups Strengthen Global Regulatory Push
  • Rising Awareness Through Global TB Campaigns Sustains Public Health-Driven Demand for Latent TB Detection
  • Public-Private Partnerships in TB Control Programs Create Opportunities for Technology Deployment at Scale
  • Growing Use of Digital Health Platforms to Track and Monitor TB Infections Drives Integration of Remote Diagnostic Tools
  • Shift Toward Decentralized Diagnostic Models Expands Reach of Latent TB Testing in Rural and Low-Infrastructure Settings
  • Demand for Pediatric TB Diagnosis Throws the Spotlight on Age-Specific Latent TB Detection Challenges and Solutions
  • Growing Global Migration Trends Spur Latent TB Testing Demand in Border and Resettlement Health Programs
  • Increased Funding From Global Health Agencies Accelerates Commercialization of Next-Generation Diagnostic Platforms
  • Healthcare System Preparedness Post-Pandemic Strengthens Focus on Infectious Disease Surveillance and Latent TB Inclusion
  • Stringent Regulatory Frameworks for TB Elimination and Surveillance Programs Create Both Compliance Pressures and Market Incentives
  • Rising Co-Infection Rates with HIV and Diabetes Drive Multidisciplinary Screening Protocols and Diagnostic Integration
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Latent Tuberculosis Infection Detection Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for QFT-Plus Brand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for QFT-Plus Brand by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for QFT-Plus Brand by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Other Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Other Brands by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Household Contacts with Pulmonary TB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Household Contacts with Pulmonary TB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Household Contacts with Pulmonary TB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for PLHIV Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for PLHIV Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for PLHIV Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Tuberculin Skin Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Tuberculin Skin Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Tuberculin Skin Test Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Interferon Gamma Released Assay Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Interferon Gamma Released Assay Test Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Interferon Gamma Released Assay Test Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals / clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospitals / clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hospitals / clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Academic & Research Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 134: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 137: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 146: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Spain Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 158: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Russia Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 183: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 197: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Australia Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 209: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: India Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: India 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 212: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 221: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: South Korea Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 233: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 245: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Latin America Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 260: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Argentina Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 272: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Brazil Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 284: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Mexico Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 296: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 308: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 309: Middle East Historic Review for Latent Tuberculosis Infection Detection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 323: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Iran Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 335: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Israel Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 347: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 359: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: UAE Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 371: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Latent Tuberculosis Infection Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 383: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Africa Historic Review for Latent Tuberculosis Infection Detection by Brand - QFT-Plus Brand and Other Brands Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by Brand - Percentage Breakdown of Value Sales for QFT-Plus Brand and Other Brands for the Years 2015, 2025 & 2030
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Latent Tuberculosis Infection Detection by Application - Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by Application - Percentage Breakdown of Value Sales for Other Applications, Household Contacts with Pulmonary TB Application and PLHIV Application for the Years 2015, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Latent Tuberculosis Infection Detection by Test Type - Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by Test Type - Percentage Breakdown of Value Sales for Tuberculin Skin Test Type and Interferon Gamma Released Assay Test Type for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Latent Tuberculosis Infection Detection by End-Use - Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Latent Tuberculosis Infection Detection by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals / clinics End-Use and Academic & Research Institutions End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION